Dr Klaus Schmierer completed his training at the Charité Hospital (Humboldt University Berlin) before moving to London to pursue a career in academic neurology. Initially working as a research fellow, from 2005 he was a Wellcome Intermediate Clinical Fellow at the UCL Institute of Neurology and then Consultant Neurologist at The National Hospital, Queen Square. Following appointments in 2009 at Queen Mary and Barts Health, he moved to his current position in East London.
MS has been a focus of Dr Schmierer’s clinical and research activities from the beginning of his training in Neurology at the Charité Hospital (Humboldt University Berlin). His clinical academic work now includes exploring the pathological substrate of disease deterioration in PwMS using MRI and quantitative histology and studies into the epidemiology and cause(s) of MS/the BartsMS Database; in vivo MRI studies to improve the differential-diagnosis of MS; and investigator-led and commercial clinical trials.
From 2013–15 Dr Schmierer served as a member of the Association of British Neurologists’ MS & Neuroinflammation Specialist Subcommittee which published the latest UK disease modifying treatment guidelines for people with MS. He has been the Deputy Director of the Research & Development Board in the Emergency Care & Acute Medicine Clinical Academic Group of Barts Health NHS Trust. He is the Past-Chair of the White Matter Study Group of the International Society for Magnetic Resonance in Medicine, and serves on the MS Society’s Clinical Trials Network, their consortium for progressive MS, as well as the review board of the MS Register. Dr Schmierer is the sub-speciality lead for MS at the NIHR North Thames Clinical Research Network, and acts as an advisor to the EMA, MHRA and NICE on new drugs for MS.
More support from MS21
Expand your knowledge
Read the latest peer-reviewed manuscripts, congress posters and patient lay summaries from the MS21 team, demonstrating our commitment to evidence-based approaches for improving MS care.
Be part of the data
Tell us about your experience in treating people with MS in one of our quick surveys – you could help to shape future MS21 resources.
Try MS support tools
Check out MS21’s free tools to improve communication with your patients and their caregivers.